Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Rybakowski JK
Potential therapeutic role of carnitine and acetylcarnitine in neurological disorders
Kailera Therapeutics #Oral #GLP-1 KAI-7535 Achieves Up to 11.1% Weight Loss and #Meets Phase 3 #Endpoints in Obesity and Type 2 Diabetes Trials in China Kailera Therapeutics and partner Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) reported positive Phase 3 results for the once-daily oral GLP-1 receptor agonist KAI-7535 (HRS-7535), moving the program closer to regulatory submission in China while expanding Kailera Therapeuticss global obesity pipeline
However, an Effectiveness Both Farxiga and Jardiance are used to treat type 2 diabetes
Side effects are typically rare and mild, such as slight pain at the injection site or mild dizziness
However, cost and insurance coverage could pose barriers, particularly in lower-income populations
